Follicular lymphoma: results of multicenter study of first-line therapy with bendamustine and rituximab, risk factors for adverse events (fl-rus-2013 protocol)

Follicular lymphoma: results of multicenter study of first-line therapy with bendamustine and rituximab, risk factors for adverse events (fl-rus-2013 protocol)

Background. Follicular lymphoma (FL) is the most common type of indolent lymphomas and accounts for 20–30 % of all non-Hodgkin’s lymphomas detected. High risk of recurrence and elderly patients make it difficult to choose induction therapy for FL. The R–B course in comparison with the R–CHOP course...

Full description

Bibliographic Details
Main Authors: E. S. Nesterova, S. K. Kravchenko, A. M. Kovrigina, E. G. Gemdzhian, L. V. Plastinina, Ya. K. Mangasarova, F. E. Babaeva, A. E. Misyurina, O. V. Margolin, A. U. Magomedova, V. I. Vorobiev, D. S. Maryin, E. A. Baryakh, Yu. Yu. Polyakov, P. A. Zeynalova, E. M. Volodicheva, N. N. Glonina, N. V. Minaeva, G. A. Davydova, V. G. Savchenko
Format: Article
Language:Russian
Published: ABV-press 2018-10-01
Series:Onkogematologiâ
Subjects:
follicular lymphoma
first line therapy
bendamustine
rituximab
prospective study
survival analysis
multivariate analysis
cumulative incidence
competing risks
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/303

Internet

https://oncohematology.abvpress.ru/ongm/article/view/303

Similar Items